Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma

BACKGROUND. Platelet-derived growth factor (PDGF) signaling is important in gliomagenesis and PDGF receptor-β is expressed on most endothelial cells in glioblastoma specimens. METHODS. We report the results of feasibility, phase I, and phase II studies of tandutinib (MLN518), an orally bioavailable...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Batchelor, Tracy T., Gerstner, Elizabeth R., Ye, Xiaobu, Desideri, Serena, Duda, Daniel G., Peereboom, David, Lesser, Glenn J., Chowdhary, Sajeel, Wen, Patrick Y., Grossman, Stuart, Supko, Jeffrey G.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5464374/
https://ncbi.nlm.nih.gov/pubmed/27663390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now185
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados